MEDIMETRIKS PHARMACEUTICALS, INC.

Commercial Dermatology Company with De-Risked, Blockbuster Phase 3 Asset MM36 (difamilast): Potential $1 Billion Product for Atopic Dermatitis in U.S.

- **Robust commercial business focused in medical dermatology**
- **MM36 is a highly selective topical PDE4 for atopic dermatitis (AD)**
  - Medimetriks owns U.S. rights for all topical indications; MM36 was developed by Otsuka Pharmaceutical Co. Ltd.
  - Annual U.S. gross sales projected to exceed $1 billion based on potential best-in-class product profile
    - Targeting >90% of the AD market represented by children and adults with mild to moderate disease
  - Successful Japanese Phase 3 trials announced March 2020 demonstrate class-leading efficacy, safety, tolerability and itch relief
  - Positive FDA Type C Meeting September 2020; Japanese Phase 3 data will support U.S. NDA
    - Preparing for one U.S. Pivotal Trial with 336 patients
  - U.S. launch anticipated in 2023; Patent protection through 2033

Foundation for Growth

1 Robust Commercial Business

Foundation for Expansion and Growth

- Portfolio of medical Dermatology brands sold through national sales force
- Commercial expertise in maximizing brand value in key medical dermatology markets
- Company infrastructure and commercial platform can be leveraged through acquisition of commercialized assets

2 Development Expertise & Lifecycle Management

Development Capabilities Support Lifecycle Management Strategy

- Line extension development provides growth potential prior to MM36 launch
  - Example: Unique brand that will compete in high potency steroid market
- Achieved FDA approval of Xepi® (ozenoxacin) cream, a topical antibiotic for impetigo December 2017
  - Divested license rights for $36 million to Cutanea Life Sciences
- Additional Authorized Generic opportunity for existing brands

3 MM36: Blockbuster Brand

Potential Peak Gross Revenues >$1 billion

- De-risked, Phase 3 topical, non-steroidal PDE4 inhibitor for mild-to-moderate AD
- Japanese Phase 3 trials in children and adults completed January 2020 demonstrate class-leading safety, efficacy, tolerability and rapid, sustained itch relief
  - Findings consistent with Phase 2 results across multiple demographics
- Over 19MM U.S. patients affected with AD; >90% of market experience mild-to-moderate symptoms

Commercial Overview

- **Growing national field force**
  - Dedicated sales force in the highest potential medical dermatology markets
  - Wide breadth and depth across Dermatology and Podiatry
- **Commercial experts in creating, launching and maximizing brands**
  - Senior Management has long-standing relationships with Key Opinion Leaders & High Volume Prescribers
- **Core brand growth drivers**

Skin & Scalp Dermatoses	
Clodan®	(clobetasol propionate)
Ketodan®	(ketoconazole foam)
NEO-SYNALAR®	(fluocinolone acetonide/neomycin)
SYNALAR®	(fluocinolone acetonide)
Tovet®	(clobetasol foam)

Acne & Rosacea	
Clindacin®	(clindamycin phosphate)
Neuac®	(clindamycin/benzoyl peroxide)
Sumadan®	(sodium sulfacetamide/sulfur)

Onychodystrophy	
Genadur®	(hydrosoluble nail lacquer)
Inflammatory Skin Conditions	
NICADAN®	(niacinamide)

MM36: Novel Topical AD Treatment

- **Phase 3 topical, non-steroidal for atopic dermatitis (AD)**
  - Unique, potent PDE4 inhibitor highly selective for PDE4 subtype B, identified as an important therapeutic target to reduce inflammation
- **MM36 has potential to be a disruptive treatment in the large, underserved AD market**
  - Successful Japanese Phase 3 trials in children and adults announced March 2020 consistent with Phase 2 findings, demonstrating potential class-leading efficacy, safety, tolerability and itch relief
    - Superior to vehicle in improving signs of AD at 4 weeks as measured by IGA (primary endpoint) and EASI
    - Safe and well-tolerated, with no reported application site stinging or burning
    - Achieved significance in rapid itch reduction at 24 hours that was sustained through 4 weeks
      - In Phase 2 trials, achieved median time to itch relief in 5.76 hours
- **Summary and key next steps**
  - Composition of Matter patent through 2033
  - Successful EoP2 FDA Meeting October 2018 & FDA Type C Meeting September 2020
  - Pivotal US Phase 3 trial planned for 2021 & commercial launch projected 2023